In:
European Journal of Haematology, Wiley, Vol. 105, No. 2 ( 2020-08), p. 185-195
Abstract:
Currently, the prognostic stratification and therapeutic evaluation systems for multiple myeloma (MM) lack specific molecular indicators. OC‐STAMP is a new gene and is also highly expressed in MM. Methods A total of 160 MM patients have been investigated with both quantitative reverse transcription PCR (RT‐qPCR), flow cytometry (FCM) and cytogenetic FISH on the same mononuclear cells isolated from bone marrow specimens. Results We found that OC‐STAMP mRNA levels were significantly higher in newly diagnosed cases of MM than in healthy donors (median, 0.52% vs. 0.02%, P 〈 .001). Moreover, the changes in the OC‐STAMP mRNA levels paralleled the disease stages and minimal residual disease, as detected by FCM. Furthermore, we found that patients with high OC‐STAMP mRNA levels were more likely to develop ≥3 bone lesions, be diagnosed with Durie‐Salmon stages III, and have the P53 (17p13) deletion. In addition, advanced stage patients with high OC‐STAMP mRNA levels had a lower 4‐year progression‐free survival (5.6% vs. 22.9%, P = .0055) and a worse 4‐year overall survival (25.8% vs. 48.8%, P = .0137) compared to patients with low mRNA levels of this indicator. Conclusions OC‐STAMP may be a promising molecular indicator to monitor treatment effects and participate in the prognostic stratification of MM.
Type of Medium:
Online Resource
ISSN:
0902-4441
,
1600-0609
Language:
English
Publisher:
Wiley
Publication Date:
2020
detail.hit.zdb_id:
2027114-1
Permalink